Table of Contents for New Drug Futures: Musculoskeletal Chapter
CURRENT MARKET SIZE 1
ANTI-RHEUMATIC DRUG SALES 3
ANTI-OSTEOPOROSIS DRUG SALES 5
ADDRESSABLE PATIENT POPULATION 6
RHEUMATOID ARTHRITIS 6
OSTEOPOROSIS 6
CURRENT TREATMENTS 7
RHEUMATOID ARTHRITIS TREATMENTS 7
OSTEOPOROSIS TREATMENTS 8
RHEUMATOID ARTHRITIS SALES DRIVERS 9
OSTEOPOROSIS SALES DRIVERS 9
RHEUMATOID ARTHRITIS SALES BREAKERS 9
OSTEOPOROSIS SALES BREAKERS 10
FUTURE TREATMENTS 11
MARKET DYNAMICS - WINNERS & LOSERS 16
KEY DRUGS LAUNCHES BY 2010 17
KEY EVALUATION CRITERIA 18
KEY MUSCULOSKELETALDRUG LAUNCHES BY 2010 19
Actemra (Roche/Chugai) 19
Novelty/rationale for mechanism of action 19
Proof of concept/clinical data 19
Management/clinical expertise 20
Competition within the marketplace/gaining share of voice 20
Risks associated with developing a drug within a therapeutic class 20
Filings and approval 21
Sales forecasts and assumptions 21
Competitor Ratio Analysis 21
Bazedoxifene (Wyeth) 21
Novelty/rationale for mechanism of action 21
Proof of concept/clinical data 22
Management/clinical expertise 22
Competition within the marketplace/gaining share of voice 22
Risks associated with developing a drug within a therapeutic class 23
Filings and approval 23
Sales forecasts and assumptions 23
Competitor Ratio Analysis 23
Cimzia (UCB/Celltech) 24
Novelty/rationale for mechanism of action 24
Proof of concept/clinical data 24
Management/clinical expertise 25
Competition within the marketplace/gaining share of voice 25
Risks associated with developing a drug within a therapeutic class 25
Filings and approval 26
Sales forecasts and assumptions 26
Competitor Ratio Analysis 26
CNTO 148 (Johnson & Johnson/Schering-Plough) 27
Novelty/rationale for mechanism of action 27
Proof of concept/clinical data 27
Management/clinical expertise 27
Competition within the marketplace/gaining share of voice 28
Risks associated with developing a drug within a therapeutic class 28
Filings and approval 28
Sales forecasts and assumptions 28
Competitor Ratio Analysis 29
Denosumab (Amgen) 29
Novelty/rationale for mechanism of action 29
Proof of concept/clinical data 29
Management/clinical expertise 30
Competition within the marketplace/gaining share of voice 30
Risks associated with developing a drug within a therapeutic class 30
Filings and approval 30
Sales forecasts and assumptions 31
Competitor Ratio Analysis 31
Entereg (GlaxoSmithKline/Adolor) 31
Novelty/rationale for mechanism of action 31
Proof of concept/clinical data 31
Management/clinical expertise 32
Competition within the marketplace/gaining share of voice 32
Risks associated with developing a drug within a therapeutic class 32
Filings and approval 33
Sales forecasts and assumptions 33
Competitor Ratio Analysis 33
Febuxostat (TAP Pharmaceutical Products) 34
Novelty/rationale for mechanism of action 34
Proof of concept/clinical data 34
Management/clinical expertise 34
Competition within the marketplace/gaining share of voice 34
Risks associated with developing a drug within a therapeutic class 34
Filings and approval 34
Sales forecasts and assumptions 35
Competitor Ratio Analysis 35
Orencia (Bristol-Myers Squibb) 35
Novelty/rationale for mechanism of action 35
Proof of concept/clinical data 35
Management/clinical expertise 36
Competition within the marketplace/gaining share of voice 36
Sales forecasts and assumptions 37
Competitor Ratio Analysis 38
Preos (NPS Pharmaceuticals) 38
Novelty/rationale for mechanism of action 38
Proof of concept/clinical data 38
POWER Study 39
PaTH Study 39
Management/clinical expertise 39
Competition within the marketplace/gaining share of voice 39
Filings and approval 40
Sales forecasts and assumptions 40
Competitor Ratio Analysis 40
COMPETITOR RATIO ANALYSIS SUMMARY 41
COMPETITOR RATIO ANALYSIS - COMPANIES 44
CMS, P&A House, Alma Road, Chesham, Bucks. HP5 3HB, UK
Tel: +44 (0)1494 771734
Fax: +44 (0)1494 778994
e-mail: keithw@cmsinfo.com
copyright © 2005 all rights reserved
For more information about us, visit CMSinfo.
